Hypophosphatasia: An overview For 2017.

  1. Inicio
  2. »
  3. Sin categoría
  4. »
  5. Hypophosphatasia: An overview For 2017.

Hypophosphatasia (HPP) is the inborn-error-of-metabolism that features low serum alkaline phosphatase (ALP) activity (hypophosphatasemia) caused by loss-of-function mutation(s) of the gene that encodes the tissue-nonspecific isoenzyme of ALP (TNSALP). Autosomal recessive or autosomal dominant inheritance from among >300 TNSALP (ALPL) mutations largely explains HPP’s remarkably broad-ranging severity. TNSALP mutation analysis BlueHost优惠码 is essential for recurrence risk assessment for HPP in future pregnancies and for prenatal diagnosis. HPP was the final rickets/osteomalacia to have a medical treatment. Now, significant successes using asfotase alfa, a mineral-targeted recombinant TNSALP, are published concerning severely affected newborns, infants, and children. Asfotase alfa was approved by regulatory agencies multinationally in 2015 typically for pediatric-onset HPP.

Bone. 2017 Feb 24. pii: S8756-3282(17)30056-X. doi: 10.1016/j.bone.2017.02.011.

Whyte MP

Patrocinadores de la web
Laboratorios Rubió
Grupo Italfármaco
Gedeon Richter
Kyowa Kirin
Meiji Pharma
Faes Farma